

- Jun 10, 2022
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma


- Apr 25, 2022
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release


- Mar 1, 2022
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6


- Aug 10, 2021
NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM


- Jun 9, 2021
NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint


- Dec 12, 2020
NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis


- Dec 10, 2020
NCT04504825: Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis


- Dec 8, 2020
NCT04258683: Phase 2: Pembrolizumab Added to the Standard First-Line therapy (CyBorD) for NDMM NTE


- Jul 17, 2020
NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)


- Jul 10, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial


- Dec 27, 2019
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)


- Dec 13, 2019
NCT03896737: Phase 2: EMN 18 - Dara-VCd VS VTd Then Maintenance With Ixazomib (IXA) or IXA-Dara


- Dec 12, 2019
NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for ASCT in Myeloma (CarMob)


- Dec 7, 2019
NCT04171843: Phase 1/2: Allogeneic anti-BCMA CAR T cells PBCAR269A With or Without Nirogacestat RRMM


- Dec 4, 2019
NCT04025216: Phase 1: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers


- Dec 7, 2018
NCT03448978: Phase 1/2 - Descartes-08 - anti-BCMA-CAR-mRNA-trans. auto CD8+ T cells in Myeloma


- Dec 7, 2018
NCT01554852: Phase 3- Thalidomide, Lenalidomide, Carfilzomib, Bortezomib, Vorinostat-NDMM Myeloma XI


- Dec 6, 2018
RADAR (UK-MRA Myeloma XV): treatment escalation and de-escalation strategies in NDMM - TE Myeloma


- Dec 7, 2017
NCT03215524: Phase 2 - Daratumumab, Low-Dose Dex and Cyclophosphamide +/- Pomalidomide (DCDP)